Skip to Content


Zachary Brennan, quoting Rachel E. Sachs (Academic Fellow Alumna)
Regulatory Affairs Professionals Society (RAPS)
February 6, 2017

Read the full article

From the article:

As far as what existing regulations if repealed would be considered part of the “two out” part of the EO, OMB notes, “Any existing regulatory action that imposes costs and the repeal or revision of which will produce verifiable savings may qualify.”

Rachel Sachs, an associate professor of law at Washington University in St. Louis, said she thinks the guidance "significantly restricts" and "walks back" the reach of the EO, particularly as it exempts big classes of regulations required by law and appreciates that regulations may be deregulatory in nature so the costs and issuance of such regulations will be considered accordingly.

Read more here!

Read the full article

Tags

bioethics   fda   health care finance   health care reform   health law policy   pharmaceuticals   rachel sachs   regulation